Search Results for "Cyclacel Limitedgb"
Original Source: Cyclacel Limited
Cyclacel Limited (Dundee, UK) uses cell cycle control biology and state-of-the-art rational drug design chemistry to develop novel cancer therapeutics including small molecule CDK inhibitors (CYC200; CYC400), Penetratin®-small molecule complexes (CYC300), Pimetic™ small molecules mimicking natural cancer suppressing genes (CYC100), and intelligent delivery and targeting systems (Penetratin® and SGC™ technologies). Cyclacel’s Polgen division (Cambridge, UK) is in a world-first effort to validate, de...
Matching Channels
None
Matching News
Cyclacel sells four disputed romidepsin-related patents to Celgene
USA based Cyclacel Pharmaceuticals (Nasdaq: CYCC) says that it has entered into a definitive agreement with biotech major Celgene (Nasdaq: CELG) to sell to Celgene four Cyclacel-owned patents related...
Public offering nets $18.8mm for [Cyclacel]
[Cyclacel Pharmaceuticals Inc.] (mainly cancer therapies; also has projects for kidney disease, diabetes, and HIV/AIDS) netted $18.8mm through public offering of 6.67mm common shares at $3 each. Proce...
Public offering nets $19.3mm for [Cyclacel]
[Cyclacel Pharmaceuticals Inc.] (mainly cancer therapies; also has projects for kidney disease, diabetes, and HIV/AIDS) netted $19.3mm through the public offering of 6.8mm common shares (including the...
[Cyclacel] and [Celgene] settle patent litigation surrounding {Istodax}
Cancer drug developers [Cyclacel Pharmaceuticals Inc.] and [Celgene Corp.] have settled three-year-old patent litigation surrounding romidepsin, the main drug in Celgene’s {Istodax}, which is market...
BERKELEY HEIGHTS, N.J., April 4, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced that it has entered into a definitive agr...
Cyclacel Pharma: Undervalued With Its Potential Blockbuster Drug
By Scott Matusow:Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat...
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Cyclacel Pharmaceuticals Inc. in a patent infringement action in which Cyclacel accused Celgene Corporation...
Cyclacel Heats Up On Clinical Trial Progression
By Brian L. Wilson:The market is beginning to bid for shares of Cyclacel Pharmaceuticals (CYCC), which hit a new 52-week high yesterday, Oct. 15. The 22.5% rally we saw by the closing bell was a react...
Matching PubMed Articles
None
